MktsMarkets

Monopar Therapeutics Inc.
NASDAQ: MNPRKey statistics
MNPR News
Stories mentioning MNPR from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | |||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | ||||||||
| Research & Development | 3,487 | 3,941 | 2,590 | 1,730 | 1,643 | 9,925 | 984.00 | 1,131 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 5,225 | 6,155 | 4,093 | 3,234 | 3,222 | 11,075 | 1,575 | 1,789 |
| Operating Income (Loss) | (5,225) | (6,155) | (4,093) | (3,234) | (3,222) | (11,075) | (1,575) | (1,789) |
| Interest Income | 1,332 | 955.00 | 655.00 | 781.00 | 597.00 | 150.00 | 99.00 | 73.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (3,893) | (5,200) | (3,438) | (2,454) | (2,625) | (10,926) | (1,304) | (1,715) |
| Earnings Per Share (Basic) | (0.46) | (0.70) | (0.48) | (0.35) | (0.38) | (2.88) | (0.37) | (0.49) |
| Earnings Per Share (Diluted) | ||||||||
| Weighted Average Shares Outstanding (Basic) | 8,535 | 7,411 | 7,124 | 6,998 | 6,987 | 3,790 | 3,520 | 3,503 |
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About MNPR
Monopar Therapeutics Inc. (NASDAQ: MNPR) is a stock listed on the Nasdaq Stock Market under the ticker symbol MNPR. It last traded at $71.42 (Nov 6, 2026, 4:00 PM ET), up 6.3% on the day. That gives Monopar Therapeutics a market capitalisation of $479.4M.
Over the past 52 weeks MNPR has traded between $50.07 and $124.82.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $3.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$3.9M |
| Dec 31, 2025 | — | -$5.2M |
| Sep 30, 2025 | — | -$3.4M |
| Jun 30, 2025 | — | -$2.5M |
From Monopar Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…